

KDL BIOTECH LIMITED
Registered Office & Works : Village Savroli, Tal. Khalapur, Dist. Raigad, Maharashtra - 410 202.

Part I

Statement of Standalone Unaudited Results for the Quarter Ended 30/06/2012

(Rs. In Lakhs)

Particulars	3 Months ended (30/06/2012)	3 Months ended (31/03/2012)	Corresponding 3 months ended in the previous year (30/06/2011)	Previous Year ended (31/03/2012) 12 months	Previous year ended (31/03/2011) 12 months
	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1. (a) Net Sales/Income from Operations (Net of excise duty)	168.41	275.11	105.67	850.22	785.16
(b) Other Operating Income (Job Work Charges Received)	315.93	255.10	400.04	1796.35	2055.47
Total Income from Operations (net)	484.34	530.21	505.70	2646.57	2840.63
2. Expenses					
a. Cost of Materials consumed	4.48	20.46	4.42	49.16	255.89
b. Purchase of stock-in-trade	111.44	113.68	82.19	420.99	482.36
c. Changes in inventories of finished goods, work-in-progress and stock-in-trade	0.00	0.00	0.00	0.00	43.34
d. Employee benefits expenses	239.94	258.44	240.15	979.42	935.63
e. Depreciation and amortisation expense	171.96	171.88	246.31	915.11	2234.81
f. Other expenses	268.96	319.86	317.89	1409.53	1384.39
Total Expenses	796.78	884.32	890.96	3774.21	5336.42
3. Profit/ (Loss) from Operations before other income, finance costs and exceptional items (1-2)	(312.44)	(354.12)	(385.26)	(1127.64)	(2495.79)
4. Other Income	8.23	17.74	8.05	51.39	45.07
5. Profit/ (Loss) from ordinary activities before finance costs and exceptional items (3+4)	(304.20)	(336.37)	(377.20)	(1076.25)	(2450.72)
6. Finance Costs	168.66	172.10	166.57	677.13	667.61
7. Profit/ (Loss) from ordinary activities after finance costs but before exceptional items (5+6)	(472.86)	(508.47)	(543.77)	(1753.37)	(3118.33)
8. Exceptional Items	0.00	0.00	0.00	46.32	(1150.00)
9. Profit / (Loss) from ordinary activities before tax (7+8)	(472.86)	(508.47)	(543.77)	(1707.05)	(4268.33)
10. Tax expense					
- Current Tax	0.00	0.00	0.00	0.00	0.00
- Deferred Tax Assets Written Off	0.00	0.00	0.00	0.00	769.27
11. Net Profit / (Loss) from ordinary activities after tax (9-10)	(472.86)	(508.47)	(543.77)	(1707.05)	(5037.59)
12. Prior Period Item	0.00	(0.86)	0.00	(16.80)	(1393.71)
13. Net Profit / (Loss) for the period (11-12)	(472.86)	(509.34)	(543.77)	(1723.86)	(6431.30)
14. Share of Profit/ (Loss) of associates (Face Value of the Share shall be indicated)	0.00	0.00	0.00	0.00	0.00
15. Minority Interest	0.00	0.00	0.00	0.00	0.00
16. Net Profit/ (Loss) after taxes, minority interest and share of profit/ (loss) of associates (13+14+15)	(472.86)	(509.34)	(543.77)	(1723.86)	(6431.30)
17. Paid-up equity share capital, Equity shares of Rs. 10 each	2,403.52	2,403.52	2,403.52	2,403.52	2,403.52
18. Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year	0.00	0.00	0.00	0.00	10,078.44
19.i Earnings Per Share (before extraordinary items) (of Rs. 10/- each) (not annualised)					
(a) Basic	(1.97)	(2.12)	(2.26)	(7.17)	(26.76)
(b) Diluted	(1.97)	(2.12)	(2.26)	(7.17)	(26.76)
19.ii Earnings Per Share (after extraordinary items) (of Rs. 10/- each) (not annualised)					
(a) Basic	(1.97)	(2.12)	(2.26)	(7.17)	(26.76)
(b) Diluted	(1.97)	(2.12)	(2.26)	(7.17)	(26.76)

KDL BIOTECH LIMITED

Registered Office : Village Savroli, Tal. : Khalapur, Dist. Raigad, Maharashtra - 410 202
Tel.: (02192) 274025 to 274030 • Fax : (02192) 274031

Part II Select Information for the Quarter Ended 30/06/2012					
	3 Months ended (30/06/2012)	3 Months ended (31/03/2012)	Corresponding 3 months ended in the previous year (30/06/2011)	Previous Year ended - (31/03/2012) 12 months	Previous year ended (31/03/2011) 12 months
A. PARTICULARS OF SHAREHOLDING					
1. Public shareholding					
- Number of shares	7,485,241	7,485,241	7,485,241	7,485,241	7,485,241
- Percentage of shareholding	31.14%	31.14%	31.14%	31.14%	31.14%
2. Promoters and Promoter Group Shareholding **					
a) Pledged / Encumbered					
- Number of shares	0.00	0.00	0.00	0.00	0.00
- Percentage of shares (as a % of the total shareholding of the Promoter and Promoter group)	0.00	0.00	0.00	0.00	0.00
- Percentage of shares (as a % of the total share capital of the company)	0.00	0.00	0.00	0.00	0.00
b) Non - Encumbered					
- Number of shares	16,549,910	16,549,910	16,549,910	16,549,910	16,549,910
- Percentage of shares (as a % of the total shareholding of the Promoter and Promoter group)	100.00%	100.00%	100.00%	100.00%	100.00%
- Percentage of shares (as a % of the total share capital of the company)	68.86%	68.86%	68.86%	68.86%	68.86%
B. INVESTOR COMPLAINTS					
Pending at the beginning of the quarter		0			
Received during the quarter		0			
Disposed of during the quarter		0			
Remaining unresolved at the end of the quarter		0			
NOTES					
1) The above un-audited results have been reviewed by the Audit Committee and taken on record approved by the Board of Directors in their meeting held on 14.08.2012					
2) Previous period figures have been regrouped or reclassified wherever necessary to make them comparable with the figures of the current period.					
3) The Company has only one segment of activity namely, "Pharmaceuticals", accordingly disclosure requirements under AS-17 for segmental information is not applicable.					
4) During the quarter no complaint/reference was received from investors and there were no Investor complaints/refermces pending at the beginning as well as at the end of the quarter.					
5) The Company had submitted revised One Time Settlement (OTS) proposal to the bankers which is pending for consent.					
6) State Bank of India, on behalf of itself and other consortium member banks, has issued notice dated April 10, 2012 u/s 13(2) of the Securitisation and Reconstruction of Financial Assets and Enforcement of Security Interest (SARFAESI) Act, 2002 to the Company and the company has replied to the said notice.					
7) The Company has made reference with BIFR on June 06, 2011. The case is registered and is pending with the BIFR for determination of status of company's sickness.					
8) The Bankers have filed suit before Debt Recovery Tribunal (DRT), Mumbai towards recovery of outstanding dues. Based on the reference made to the BIFR by the Company, DRT has stayed the matter in view of the reference to BIFR.					
9) The Company has not provided for the penal interest and additional interest on defaults in payment of installments and interest on credit facilities from banks, the amount of which is unascertained. The auditors have qualified their limited review report for this matter. The Company's management believes that pending finality of the reference filed with BIFR, no penal interest and additional interest needs to be accrued on the loans at this point of time.					
For and on behalf of the Board of Directors  Dr. Rajesh Agarwal Director					
Place : Mumbai Dated : August 14, 2012					

KDL BIOTECH LIMITED

Corporate Office : ~~1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100~~

Registered Office & Works : Village Savroli, Tal. : Khalapur, Khopoli, Dist. Raigad, Maharashtra-410 202

Tel.: (02192) 274025 to 274030 • Fax : (02192) 274031